A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Responsible Party:
Eli Lilly and Company

ClinicalTrials.gov Identifier:

Other Study ID Numbers:
18582J1I-MC-GZBM ( Other Identifier: Eli Lilly and Company )2023-503659-88-00 ( Other Identifier: EU Trial Number )

First Posted:
May 31, 2023    Key Record Dates

Last Update Posted:
June 13, 2023

Last Verified:
June 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Plan Description:
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting Materials:
Study ProtocolStatistical Analysis Plan (SAP)Clinical Study Report (CSR)

Time Frame:
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access Criteria:
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.


Home – GREI

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 14, 2023Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine